🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
WST
NYSE
🇺🇸 US
West Pharmaceutical Services
Healthcare
28Score
DipBuster Score™
$344.25
+$7.31 (+2.17%)
Live price · Source: Yahoo
52-Week Position
$223.83
74% of range
$386.00
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
BetaN/A
52W High$386.00
52W Low$223.83
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Neutral
Mid-Range Position (74% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position74% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta—
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at West Pharmaceutical Services (WST), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-06-30 | Haugen Janet Brutschea | BUY | 46 |
| 2026-05-12 | Campbell Shane Alden | SELL | 474 |
| 2026-05-12 | Campbell Shane Alden | SELL | 296 |
| 2026-05-12 | Campbell Shane Alden | SELL | 135 |
| 2026-05-12 | Campbell Shane Alden | BUY | 474 |
| 2026-05-12 | Campbell Shane Alden | SELL | 84 |
| 2026-05-12 | Campbell Shane Alden | BUY | 296 |
| 2026-05-04 | Friel Robert F | BUY | 791 |
| 2026-05-04 | Feehery William F | BUY | 791 |
| 2026-05-04 | Pucci Paolo | BUY | 791 |
Graham NCAV Analysis
Above net-net level
Current Assets$1.98B
Less: Total Liabilities−$1.09B
= Net Current Asset Value$884.2M
NCAV Per Share$11.7356
Current Price$339.97
Price / NCAV28.97×
Margin of Safety-2796.9%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
BetaN/A
Dividend/yrNone
52W High$386.00
52W Low$223.83
52-Week Range
$223.83Now$386.00
74% through annual range
From 52W High−10.8%
From 52W Low+53.8%
📖 Plain English Summary
West Pharmaceutical Services is at 74% of its 52-week range.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for WST
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — WST
Heuristic · balance sheet, insider filings, price data, academic research
West Pharmaceutical Services — DipBuster Score 28/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track West Pharmaceutical Services free
Add WST to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
10/25
Momentum & Volume
13/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
4
/100 · NEUTRAL
dip depth
2/25
oversold rsi
0/25
mean reversion
2/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 28/100
📈
Strong recent momentum — price and volume trending in the right direction.